AstraZeneca: successful phase III trial in Covid
(CercleFinance.com) - AstraZeneca announced on Monday that the phase III trial devoted to its AZD7442 antibody had met its primary endpoint by "significantly" reducing the risk of developing a severe form of Covid-19, or even dying from it.
Administered as an intramuscular injection, the treatment reduced these risks by 50% in patients who had been symptomatic for less than a week.
In the AZD7442 group, only 18 negative "events" were recorded, out of 407 patients recruited, compared with 37 in the placebo group.
The trial focused on non-hospitalised patients with mild-to-moderate forms of the disease. However, almost 90% of the participants were from so-called high-risk populations, due to their comorbidities.
AstraZeneca shares were up 0.2% on Monday morning, just outperforming the index in London (+0.1%).
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Administered as an intramuscular injection, the treatment reduced these risks by 50% in patients who had been symptomatic for less than a week.
In the AZD7442 group, only 18 negative "events" were recorded, out of 407 patients recruited, compared with 37 in the placebo group.
The trial focused on non-hospitalised patients with mild-to-moderate forms of the disease. However, almost 90% of the participants were from so-called high-risk populations, due to their comorbidities.
AstraZeneca shares were up 0.2% on Monday morning, just outperforming the index in London (+0.1%).
Copyright (c) 2021 CercleFinance.com. All rights reserved.